Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420640 | 1.00 | MAPT (0.49) | MAPTMEN1KMT2AFLT1FLT4 | |
| SCHEMBL30753064 | 0.83 | KDM4E (0.53) | FLT1FLT4KDRMYCNR4A1 | |
| SCHEMBL3173571 | 0.83 | FLT1 (0.46) | MAPTMEN1KMT2AFLT1FLT4 | |
| SCHEMBL6360 | 0.83 | KDM4E (0.53) | FLT1FLT4KDRMYCNR4A1 | |
| SCHEMBL9353897 | 0.83 | MAOA (0.50) | MAPTMEN1KMT2AMAOAPTGDR2 | |
| SCHEMBL30976481 | 0.83 | MAOA (0.50) | MAPTMEN1KMT2AMAOAPTGDR2 | |
| SCHEMBL30864269 | 0.82 | MAOA (0.53) | MAPTMAOAPTGDR2MAOBDGAT1 | |
| Hydrochloric Acid SCHEMBL7676438 | 0.81 | KDM4E (0.52) | MEN1KMT2AFLT1FLT4KDR | |
| SCHEMBL321933 | 0.81 | FLT1 (0.49) | MAPTMEN1KMT2AFLT1FLT4 | |
| SCHEMBL428805 | 0.81 | DGAT1 (0.60) | MAPTMEN1KMT2AFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081215-B1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4051680-B1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-12220401-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240327380-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024120424-A1 | COMPOUND TARGETING PAN-KRAS PROTEIN DEGRADATION AGENT AND USE THEREOF | 贝达药业股份有限公司 | 2024-06-13 | — | — | WO | disclosed |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | MSD K.K. (JP) | 2008-05-01 | — | — | US | disclosed |
| WO-2008020203-A1 | PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
| EP-1813613-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
| EP-0777650-B1 | BIPHENYLAMIDE DERIVATIVES AS 5HT 1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2001-03-07 | — | — | EP | disclosed |
| US-5817833-A | Biphenylamide compounds as 5HT1D Antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-10-06 | — | — | US | disclosed |
| EP-0777650-A1 | BIPHENYLAMIDE DERIVATIVES AS 5HT 1D? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-06-11 | — | — | EP | disclosed |
| WO-1996006079-A1 | BIPHENYLAMIDE DERIVATIVES AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | MAPT 4604/4885MEN1 2255/4885KMT2A 1735/4885 |
| US-12220401-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | MAPT 3956/4885MEN1 2243/4885KMT2A 688/4885 |
| US-20240327380-A1 | BTK INHIBITORS | BTK, SYK, LYN | MAPT 3396/4885MEN1 1186/4885KMT2A 831/4885 |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | MAPT 3956/4885MEN1 2243/4885KMT2A 688/4885 |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | MAPT 2709/4885MEN1 677/4885KMT2A 165/4885 |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | MAPT 2903/4885MEN1 4865/4885KMT2A 3031/4885 |
| US-20080103136-A1 | Novel Fused Imidazole Derivative | HRH4, H1-4, H1-3 | MAPT 4346/4885MEN1 1505/4885KMT2A 1819/4885 |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | ABL1, CDK1, CDK2 | MAPT 4247/4885MEN1 1448/4885KMT2A 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.